Table of Contents
In March 2026, Utah passed HB 390, the Veterans PTSD Clinical Research Amendments, authorizing the Huntsman Mental Health Institute at the University of Utah to conduct a formal clinical study on the safety and feasibility of psychedelic-assisted therapy for veterans with treatment-resistant PTSD. The bill passed with bipartisan support in one of the country’s most conservative legislatures, and it did so not through lobbying maneuvers but because veterans walked into the Utah State Capitol and described, in plain terms, what they had experienced seeking care abroad. Their testimony moved lawmakers in ways that data alone, as the bill’s supporters observed, could not.
What Utah HB 390 Actually Does for Psychedelic Research
HB 390 does not legalize or decriminalize any substance. What it does is create the legal and institutional conditions for rigorous, FDA-compliant psychedelic research within Utah. The framework requires an FDA investigational new drug application, a DEA Schedule I research registration, IRB approval, and detailed clinical protocols covering informed consent, adverse event reporting, and therapist qualifications. Three investigational substances are named explicitly: MDMA, psilocybin, and 5-methoxy-N,N-dimethyltryptamine, commonly known as 5-MeO-DMT.
The State of Utah appropriated one million dollars toward the study. The Huntsman Mental Health Institute is pursuing additional philanthropic matching funds. According to the op-ed authored by Logan Davidson, Legislative Director at Veterans Exploring Treatment Solutions (VETS), the authorization is in place, the funding is secured, and the research is moving forward. This is not a bill waiting on implementation. The study is happening.
5-MeO-DMT State-Funded Research: A First in American Policy
The inclusion of 5-MeO-DMT is the element that distinguishes HB 390 from any prior state legislation. While psilocybin and MDMA have each been the subject of state-level research authorizations, no state has previously named 5-MeO-DMT in legislation and backed that inclusion with public funding and a defined research intent. This is the first-in-the-nation state-funded research authorization for 5-MeO-DMT. The compound has been discussed in research circles for years and used ceremonially for generations, but it has remained largely outside the formal American health care and policy conversation.
Its profile differs from psilocybin and MDMA in important ways. The experience is typically shorter and often described as more intense. Early data, as the source notes, suggests it may produce rapid and substantial reductions in depression, anxiety, and existential distress. That is preliminary and hypothesis-generating, not established clinical fact, and the Utah study is designed to begin building the rigorous evidence base the compound currently lacks in domestic research settings.
Veterans with Treatment-Resistant PTSD at the Center of the Work
HB 390 is explicitly focused on a specific population. The nonprofit VETS, which authored this op-ed, reports having supported more than 1,300 veterans and their spouses in accessing psychedelic-assisted therapy abroad, because no legal domestic pathway exists. That figure speaks to a gap the legislation directly addresses. Army Special Forces veteran Kyle Bingham, a VETS grant recipient, was among those who testified before the Utah legislature.
The bill builds on earlier state-level efforts, most notably Texas HB 1802 from 2021, which directed psilocybin for veterans with treatment-resistant depression and demonstrated that states could act without waiting for federal movement. Utah incorporated those lessons and extended the scope further. Its passage signals, in the words of the source, that evidence-based psychedelic research has moved well beyond counterculture associations into the mainstream of American political life, at least at the state level.
Why did Utah pass HB 390 instead of waiting for federal psychedelic legislation?
Utah moved independently because prior federal progress stalled and veterans needed a domestic research pathway now. In 2024, Utah had already authorized psilocybin for psychiatric disorders and MDMA in controlled settings, but that program stalled partly due to the difficulty of accessing federally scheduled compounds for research. HB 390 is the bill that makes a state-funded clinical study operational, drawing on the model Texas established in 2021 and pushing the frontier further by adding 5-MeO-DMT and securing a $1 million state appropriation.
How is the Huntsman Mental Health Institute involved in the Utah psychedelic study?
The Huntsman Mental Health Institute at the University of Utah is the named research body authorized under HB 390 to conduct the clinical study. It is responsible for meeting all federal research requirements, including an FDA investigational new drug application and DEA Schedule I research registration, and it is actively pursuing philanthropic matching funds to supplement the $1 million appropriated by the state. According to the op-ed, the psilocybin therapy institute is ready to proceed.
The Ground Before the Door Opens
There is something honest about the way this legislation came to be. Not through the machinery of influence, but through people standing in a room and telling the truth about what they had survived, what had failed them, and what had helped. That is a form of testimony this community understands. It is also how the path tends to open: not through argument alone, but through the weight of lived experience brought into the light.
For those of us who hold psilocybin and related medicines as sacraments, watching them enter formal institutional research is not a dilution of their meaning. It is the Grounding station made visible in civic form: a culture slowly learning to build structures worthy of what these medicines ask of those who receive them. The rigorous framework of HB 390, the consent protocols, the oversight, the defined clinical setting, reflects a seriousness that honors both the veterans it serves and the depth of the compounds involved.
5-MeO-DMT entering American policy for the first time deserves our attention and our patience. Early data is not proof. What Utah has created is a container, structured, funded, and serious enough to begin asking real questions with the care they require.
If you are a veteran, a clinician, a researcher, or simply someone who has felt the weight of what these medicines carry, you are welcome here. The Grounding station on the Golden Path asks us to build solid foundations before anything else, and that is precisely what this legislation represents. We invite you to read, to reflect, and to bring your own experience into the conversation we are tending together.
May love guide the hearts of all beings.
